From permeability to prediction: evolving strategies for evaluating oral drug absorption
Clinical Snapshot
PICO Framework
| P — Population | Not applicable - this is a narrative review examining methodologies rather than patient populations |
| I — Intervention | Emerging methodologies for oral drug absorption assessment (organoid-on-chip, computational modeling, AI platforms) |
| C — Comparator | Classical permeability assays (PAMPA, Caco-2, Ussing chambers, intestinal perfusion) |
| O — Outcomes | Predictive accuracy, physiological relevance, scalability, and clinical translation potential of absorption assessment methods |
Bottom Line
This narrative review examines the evolution of oral drug absorption assessment methodologies, highlighting limitations of classical approaches like PAMPA and Caco-2 models in predicting clinical bioavailability. While mechanistic studies using advanced imaging provide biological insights, they lack scalability for drug development. Emerging organoid-on-chip platforms and computational modeling show promise for bridging the gap between in vitro testing and clinical outcomes. However, the review lacks systematic methodology and quantitative synthesis typical of high-quality evidence reviews. The integration of artificial intelligence with biomimetic models represents a promising future direction, but requires standardisation and regulatory alignment. For pharmaceutical development teams, this provides a useful overview of evolving technologies, though specific implementation guidance remains limited. The emphasis on multiscale prediction platforms aligns with current regulatory trends toward model-informed drug development approaches.
Key Findings
Effect Size: Not applicable - narrative review without quantitative synthesis
Primary Outcome: Evolution from classical permeability assays to integrated predictive platforms
Nnt Or Sensitivity: Classical methods show limited physiological relevance; emerging platforms offer improved predictive accuracy but face scalability challenges
Clinical Application
Emerging technologies require significant infrastructure investment and standardisation before widespread implementation Relevant to TGA regulatory pathways for oral drug approval; aligns with Australian pharmaceutical research priorities in drug delivery systems Pharmaceutical researchers, drug development scientists, and regulatory professionals involved in oral drug formulation
Abstract
Oral drug administration, preferred for patient compliance and convenience, encounters significant bioavailability challenges arising from complex physicochemical, physiological, and formulation-related barriers. Traditional models for evaluating absorption exhibit limitations in physiological relevance and predictive accuracy. This review critically examines evolving methodologies for oral drug absorption assessment, from classical permeability assays to emerging predictive platforms, emphasizing integration of mechanistic research with predictive modeling to advance intelligent platforms and clinical translation. While classical permeability models including parallel artificial membrane permeability assay (PAMPA), Caco-2, Ussing chambers, and intestinal perfusion remain indispensable for early screening, their limited physiological relevance and inability to elucidate mechanistic pathways constrain predictive accuracy. Mechanistic approaches such as lymphatic transport studies and advanced tracking techniques using fluorescence, Single Photon Emission Computed Tomography (SPECT), or Positron Emission Tomography (PET) imaging reveal critical biological pathways but suffer from scalability challenges. Emerging platforms provide transformative potential, as organoid-on-a-chip offer physiologically relevant and high-throughput alternatives, while integrated computational modeling enables multiscale prediction, from molecular interactions to systemic pharmacokinetics. Future oral absorption assessment requires converging in vitro biomimetics, computational modeling, and Artificial intelligence (AI) within unified platforms. Achieving this requires standardized in vitro models, robust data integration, and alignment with regulatory to accelerate translational drug development.
References
- 1.Yang, Z., Chen, K., Wang, Y., Li, J., He, Y., Zhuang, J., & Qi, J. (2026). From permeability to prediction: evolving strategies for evaluating oral drug absorption. International Journal of Pharmaceutics, 126725. https://doi.org/10.1016/j.ijpharm.2026.126725
Related Research
CPT: pharmacometrics & systems pharmacology
Structured Schemas for Provenance-Rich, LLM-Assisted QSP Model Calibration
2 Aug 2026
Journal of pharmacokinetics and pharmacodynamics
Diffusion models for virtual populations and pharmacometric simulations
1 Aug 2026
Journal of chemical information and modeling
HyperDC: A Non-Uniform Hypergraph Framework for Dual- and Higher-Order Drug Combination Recommendation Across Diverse Complex Diseases
29 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service